Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641561 · ClinicalTrials.gov registry record · Phase 3
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
A Phase 3 study, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT02641561 is a Phase 3 study that has completed, run by The Cooper Health System. The registered enrollment target is 192 participants.
The verdict
NCT02641561, a Phase 3 study, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
Post-ERCP pancreatitis is a well-known and sometimes life-threatening complication of ERCP. Both LR and rectal indomethacin have shown benefit in preventing post-ERCP pancreatitis. Despite this, no study to date has evaluated both of these measures for preventing post-ERCP pancreatitis. It is our hope to evaluate the combination of these two modalities for preventing post-ERCP pancreatitis compared with either modality alone.
Interventions
- DRUG Placebo
- DRUG Indomethacin
- DRUG Normal Saline
- DRUG Lactated Ringer's Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02641561
The ClinicalTrials.gov registry entry for NCT02641561 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02641561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02641561 about?
NCT02641561 is a clinical study titled "Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis". Post-ERCP pancreatitis is a well-known and sometimes life-threatening complication of ERCP. Both LR and rectal indomethacin have shown benefit in preventing post-ERCP pancreatitis. Despite this, no study to date has evaluated both of these measures for preventing post-ERCP pancreatitis. It is our ho...
What is the current status of trial NCT02641561?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2014-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02641561?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG), Normal Saline (DRUG), Lactated Ringer's Solution (DRUG).
Who is sponsoring clinical trial NCT02641561?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.